|
Median, Age – median (range)
|
61 (45-85)
|
61 (24-82)
|
61 (24-85)
|
0.859
|
|
Race– no. (%)
| | | |
0.339
|
|
Caucasian
|
14 (74)
|
16 (70)
|
30 (71)
| |
|
African-American
|
5 (26)
|
4 (17)
|
9 (21)
| |
|
Asian
|
0 (0)
|
3 (13)
|
3 (7)
| |
|
Histology– no. (%)
| | | |
0.330
|
|
Clear Cell
|
17 (89)
|
16 (70)
|
33 (79)
| |
|
Non-Clear cell
|
2 (11)
|
9 (30)
|
9 (21)
| |
|
Smoking Status– no. (%)
| | | |
>0.99
|
|
No
|
10 (53)
|
11 (48)
|
21 (50)
| |
|
Yes
|
9 (47)
|
12 (52)
|
21 (50)
| |
|
Number of Prior anti-VEGF Therapies– no. (%)
| | | |
0.093
|
|
≤1
|
16 (84)
|
13 (57)
|
29 (69)
| |
|
> 1
|
3 (16)
|
10 (43)
|
13 (31)
| |
|
Duration of prior anti-VEGF Therapies– no. (%)
| | | |
>0.99
|
|
< 6 Months
|
8 (42)
|
10 (43)
|
18 (43)
| |
|
≥ 6 Months
|
11 (58)
|
13 (57)
|
24 (57)
| |
|
NLR at Day 15– no. (%)
| | | |
<0.001
|
|
< 3
|
15 (79)
|
2 (9)
|
17 (40)
| |
|
≥ 3
|
4 (21)
|
20 (87)
|
24 (57)
| |
|
NLR at Cycle 3– no. (%)a
| | | |
0.001
|
|
< 3
|
13 (68)
|
3 (13)
|
16 (38)
| |
|
≥ 3
|
4 (21)
|
16 (70)
|
20 (48)
| |
|
Types of anti-VEGF Therapies – no. (%)
| | | | |
|
Pazopanib
|
10 (34)
|
10 (77)
|
20 (48)
|
0.019
|
|
Sunitinib
|
6 (21)
|
9 (69)
|
15 (36)
|
0.005
|
|
Axitinib
|
0 (0)
|
9 (69)
|
9 (21)
|
<0.001
|
|
Sorafenib
|
0 (0)
|
6 (46)
|
6 (14)
|
<0.001
|
|
Bevacizumab
|
2 (7)
|
5 (38)
|
7 (17)
|
0.021
|
|
Everolimus
|
2 (7)
|
5 (38)
|
7 (17)
|
0.021
|
|
IL2
|
10 (34)
|
10 (77)
|
20 (48)
|
0.019
|
|
Histology – no. (%)
| | | |
0.330
|
|
Clear
|
17 (89)
|
16 (70)
|
33 (79)
| |
|
Clear Cell W/ Sarcamatoid Features
|
0 (0)
|
3 (13)
|
3 (7)
| |
|
Clear Cell W/ Papillary Features
|
2 (1)
|
3 (13)
|
5 (12)
| |
|
Medullary
|
0 (0)
|
1 (4)
|
1 (2)
| |
|
Heng Prognostic Score– no. (%)
| | | |
0.509
|
|
Low
|
4 (21)
|
8 (35)
|
12 (29)
| |
|
Intermediate
|
10 (53)
|
12 (52)
|
22 (52)
| |
|
High
|
5 (26)
|
3 (13)
|
8 (19)
| |
|
MSKCC Prognostic Score– no. (%)
| | | |
0.317
|
|
Low
|
4 (21)
|
9 (39)
|
13 (31)
| |
|
Intermediate
|
15 (79)
|
14 (61)
|
29 (69)
| |
|
Type of Immune Checkpoint Inhibitor Therapy– no. (%)
| | | |
0.220
|
|
Nivolumab
|
19 (66)
|
10 (77)
|
29 (69)
| |
|
Nivolumab plus Nexavar
|
0 (0)
|
1 (8)
|
1 (2)
| |
|
Nivolumab plus Votrient
|
1 (3)
|
2 (15)
|
3 (7)
| |
|
Nivolumab + Ipilimumab
|
1 (3)
|
0 (0)
|
1 (2)
| |
|
Ipilimumab
|
0 (0)
|
0 (0)
|
0 (0)
| |
|
Avelumab
|
1 (3)
|
0 (0)
|
1 (2)
| |
|
Pembrolizumab and Axitinib
|
5 (17)
|
0 (0)
|
5 (12)
| |
|
Atezolizumab and Avastin
|
2 (7)
|
0 (0)
|
2 (5)
| |
